Rare & Genetic · Clinical trials
Gaucher Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About gaucher disease — and why its trials are hard
Gaucher disease is an autosomal-recessive lysosomal storage disorder caused by mutations in the GBA1 gene, leading to deficient glucocerebrosidase activity and accumulation of glucosylceramide in macrophages (Gaucher cells). Type 1, the most common non-neuronopathic form, presents with hepatosplenomegaly, anaemia, thrombocytopenia and bone disease; types 2 and 3 add acute or chronic neurological involvement. Two pharmacological strategies dominate. Enzyme replacement therapy (ERT) supplies recombinant glucocerebrosidase—imiglucerase (Cerezyme), velaglucerase alfa (VPRIV) and taliglucerase alfa (Elelyso)—given by intravenous infusion to reverse visceral and haematological manifestations. Substrate reduction therapy (SRT) uses oral inhibitors of glucosylceramide synthase—miglustat (Zavesca) and the more potent, better-tolerated eliglustat (Cerdelga)—to reduce substrate production. ERT is highly effective for type 1 and remains the mainstay, while eliglustat offers an oral first-line alternative in appropriate CYP2D6 metabolisers. Neither adequately treats the neurological features of types 2 and 3. Key endpoints include haemoglobin, platelet count, and spleen and liver volumes; bone outcomes evolve more slowly.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Imiglucerase (Cerezyme) | 1994 | Enzyme replacement for type 1 Gaucher disease (and non-neurological manifestations of type 3) | Registration studies of recombinant glucocerebrosidase | Improvement in haemoglobin, platelet count, and organ (spleen/liver) volumes | Substantial normalisation of cytopenias and reduction in organomegaly with maintenance dosing |
| Velaglucerase alfa (VPRIV) | 2010 | Enzyme replacement for type 1 Gaucher disease | Phase 3 (including head-to-head vs imiglucerase) | Change in haemoglobin, platelets, and spleen/liver volume | Significant haemoglobin rise and organ-volume reduction; comparable to imiglucerase |
| Eliglustat (Cerdelga) | 2014 | Oral substrate reduction, first-line for type 1 Gaucher in CYP2D6 EM/IM/PM (not URM/indeterminate) | ENGAGE (treatment-naive) and ENCORE (switch from ERT) | ENGAGE: reduction in spleen volume; ENCORE: non-inferiority to imiglucerase on composite stability | ENGAGE: ~28% reduction in spleen volume vs placebo; ENCORE met non-inferiority to ERT |
| Taliglucerase alfa (Elelyso) | 2012 | Plant cell-expressed enzyme replacement for type 1 Gaucher disease | Phase 3 registration study | Change in spleen volume, haemoglobin and platelets | Significant reductions in organ volume and improvement in haematological parameters |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in gaucher disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Afegostat (isofagomine, AT2101, pharmacological chaperone) — Phase 2 in type 1 Gaucher disease | Did not meet efficacy expectations and development was discontinued | Insufficient clinical improvement in haematological and organ endpoints; the chaperone approach did not deliver adequate glucocerebrosidase enhancement |
Choosing the right endpoint
Primary endpoints that matter in gaucher disease trials
- Haemoglobin concentration — Correction of anaemia is a core efficacy measure for ERT and SRT in type 1 disease
- Platelet count — Improvement in thrombocytopenia reflects reversal of splenic sequestration and marrow involvement
- Spleen and liver volume — Reduction in organomegaly (often MRI-measured, in multiples of normal) is a primary endpoint in pivotal trials
- Skeletal / bone outcomes — Bone marrow burden, bone mineral density and bone pain improve more slowly and are important long-term measures
How iNGENū runs gaucher disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Gaucher Disease clinical trials — FAQs
What is the difference between ERT and SRT?
Why does CYP2D6 genotype matter for eliglustat?
Do these therapies treat neurological Gaucher disease?
Ready to discuss your gaucher disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal